 Katharina Hopp
Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Kidney, Autosomal Dominant | 28 | 2025 | 260 | 6.400 |
Why?
| | TRPP Cation Channels | 18 | 2025 | 84 | 3.250 |
Why?
| | Polycystic Kidney Diseases | 10 | 2025 | 76 | 2.590 |
Why?
| | Kidney | 18 | 2025 | 1467 | 2.090 |
Why?
| | Mutation | 14 | 2022 | 3956 | 1.120 |
Why?
| | Energy Metabolism | 4 | 2024 | 920 | 1.070 |
Why?
| | Tryptophan | 2 | 2023 | 183 | 0.760 |
Why?
| | Adaptive Immunity | 2 | 2020 | 165 | 0.700 |
Why?
| | Renal Agents | 1 | 2020 | 5 | 0.670 |
Why?
| | Caloric Restriction | 1 | 2020 | 123 | 0.590 |
Why?
| | Cysts | 5 | 2025 | 111 | 0.590 |
Why?
| | Mice, Inbred C57BL | 15 | 2025 | 5753 | 0.560 |
Why?
| | Disease Models, Animal | 15 | 2025 | 4284 | 0.530 |
Why?
| | Mice | 23 | 2025 | 17774 | 0.490 |
Why?
| | Hyperoxaluria, Primary | 1 | 2015 | 14 | 0.460 |
Why?
| | Hepatocyte Nuclear Factor 1-beta | 1 | 2014 | 4 | 0.460 |
Why?
| | Arginine Vasopressin | 1 | 2014 | 44 | 0.460 |
Why?
| | Receptors, Vasopressin | 1 | 2014 | 20 | 0.460 |
Why?
| | Mutation, Missense | 4 | 2015 | 338 | 0.460 |
Why?
| | DNA Mutational Analysis | 3 | 2014 | 400 | 0.460 |
Why?
| | Kidney Failure, Chronic | 2 | 2020 | 566 | 0.450 |
Why?
| | TOR Serine-Threonine Kinases | 3 | 2025 | 412 | 0.450 |
Why?
| | Genetic Loci | 2 | 2013 | 289 | 0.450 |
Why?
| | Somatostatin | 1 | 2014 | 61 | 0.440 |
Why?
| | Benzazepines | 1 | 2014 | 39 | 0.440 |
Why?
| | Animals | 29 | 2025 | 36862 | 0.430 |
Why?
| | Heterozygote | 1 | 2015 | 292 | 0.430 |
Why?
| | Metabolome | 3 | 2022 | 350 | 0.430 |
Why?
| | Genetic Association Studies | 2 | 2016 | 377 | 0.430 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2021 | 916 | 0.410 |
Why?
| | Encephalocele | 1 | 2011 | 9 | 0.360 |
Why?
| | Ciliary Motility Disorders | 1 | 2011 | 24 | 0.350 |
Why?
| | Protein Folding | 1 | 2012 | 281 | 0.350 |
Why?
| | Disease Progression | 5 | 2022 | 2752 | 0.340 |
Why?
| | Patient Selection | 1 | 2014 | 692 | 0.340 |
Why?
| | Sequence Deletion | 1 | 2011 | 183 | 0.340 |
Why?
| | Kidney Diseases | 1 | 2014 | 406 | 0.340 |
Why?
| | Decision Support Techniques | 1 | 2014 | 418 | 0.340 |
Why?
| | Exons | 1 | 2011 | 351 | 0.320 |
Why?
| | Phenotype | 8 | 2022 | 3202 | 0.320 |
Why?
| | Macrophages | 3 | 2025 | 1544 | 0.280 |
Why?
| | Tumor Microenvironment | 3 | 2021 | 674 | 0.270 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2019 | 189 | 0.260 |
Why?
| | Mice, Transgenic | 3 | 2018 | 2164 | 0.260 |
Why?
| | Polycystic Kidney, Autosomal Recessive | 2 | 2019 | 6 | 0.250 |
Why?
| | Metabolomics | 2 | 2022 | 679 | 0.250 |
Why?
| | Mice, Knockout | 6 | 2025 | 3009 | 0.240 |
Why?
| | Alleles | 3 | 2018 | 892 | 0.240 |
Why?
| | Glomerular Filtration Rate | 3 | 2024 | 745 | 0.240 |
Why?
| | Pedigree | 7 | 2018 | 514 | 0.240 |
Why?
| | Kynurenine | 2 | 2023 | 114 | 0.230 |
Why?
| | Lymphoid Tissue | 1 | 2025 | 75 | 0.230 |
Why?
| | Proteins | 1 | 2011 | 1012 | 0.230 |
Why?
| | Mice, Mutant Strains | 2 | 2022 | 298 | 0.220 |
Why?
| | Ureteral Obstruction | 2 | 2021 | 64 | 0.210 |
Why?
| | B7-1 Antigen | 1 | 2023 | 58 | 0.210 |
Why?
| | Tryptophan Oxygenase | 1 | 2023 | 34 | 0.200 |
Why?
| | Fibrosis | 3 | 2021 | 552 | 0.200 |
Why?
| | Lipoxygenase Inhibitors | 2 | 2021 | 37 | 0.200 |
Why?
| | Lung Neoplasms | 3 | 2021 | 2494 | 0.200 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 56 | 0.200 |
Why?
| | Kidney Tubules | 3 | 2019 | 117 | 0.190 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2021 | 18 | 0.190 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2021 | 23 | 0.190 |
Why?
| | Humans | 26 | 2024 | 137294 | 0.190 |
Why?
| | Nephritis | 1 | 2021 | 22 | 0.190 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 1078 | 0.180 |
Why?
| | Epithelial Cells | 4 | 2025 | 1095 | 0.180 |
Why?
| | Male | 24 | 2025 | 67560 | 0.180 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 218 | 0.180 |
Why?
| | Female | 22 | 2024 | 73052 | 0.170 |
Why?
| | Databases, Genetic | 1 | 2022 | 237 | 0.170 |
Why?
| | Trehalose | 1 | 2020 | 32 | 0.170 |
Why?
| | Monocytes | 1 | 2023 | 563 | 0.170 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1237 | 0.170 |
Why?
| | Nutritive Value | 1 | 2020 | 37 | 0.160 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2019 | 429 | 0.160 |
Why?
| | Naphthyridines | 1 | 2019 | 19 | 0.160 |
Why?
| | Cilia | 3 | 2022 | 177 | 0.160 |
Why?
| | Cardiomegaly | 1 | 2020 | 175 | 0.150 |
Why?
| | Receptors, Cell Surface | 2 | 2019 | 386 | 0.150 |
Why?
| | Chemokines | 1 | 2020 | 228 | 0.150 |
Why?
| | Protein Kinase C | 1 | 2020 | 261 | 0.150 |
Why?
| | Mosaicism | 1 | 2019 | 73 | 0.150 |
Why?
| | Orofaciodigital Syndromes | 1 | 2018 | 1 | 0.150 |
Why?
| | Cell Cycle Proteins | 2 | 2019 | 613 | 0.150 |
Why?
| | Ciliopathies | 1 | 2018 | 6 | 0.150 |
Why?
| | Tandem Mass Spectrometry | 1 | 2022 | 532 | 0.150 |
Why?
| | Inflammation Mediators | 1 | 2021 | 514 | 0.150 |
Why?
| | Cell Line | 3 | 2020 | 2841 | 0.150 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2020 | 368 | 0.150 |
Why?
| | HSP40 Heat-Shock Proteins | 1 | 2018 | 27 | 0.140 |
Why?
| | Trans-Activators | 1 | 2020 | 398 | 0.140 |
Why?
| | Sirolimus | 1 | 2019 | 275 | 0.140 |
Why?
| | Microtubule-Associated Proteins | 1 | 2018 | 195 | 0.130 |
Why?
| | Amino Acid Sequence | 4 | 2018 | 2147 | 0.130 |
Why?
| | Energy Intake | 1 | 2020 | 484 | 0.130 |
Why?
| | alpha-Glucosidases | 1 | 2016 | 9 | 0.130 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 1 | 1 | 2015 | 3 | 0.120 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2015 | 10 | 0.120 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 537 | 0.120 |
Why?
| | Interferon-gamma | 1 | 2019 | 790 | 0.120 |
Why?
| | Adult | 9 | 2024 | 37724 | 0.120 |
Why?
| | Hypodermoclysis | 1 | 2014 | 4 | 0.120 |
Why?
| | Nuclear Proteins | 1 | 2020 | 712 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 2 | 2022 | 2419 | 0.110 |
Why?
| | Drinking | 1 | 2014 | 42 | 0.110 |
Why?
| | Antidiuretic Agents | 1 | 2014 | 6 | 0.110 |
Why?
| | Antidiuretic Hormone Receptor Antagonists | 1 | 2014 | 9 | 0.110 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2014 | 12 | 0.110 |
Why?
| | Biomarkers | 3 | 2021 | 4164 | 0.110 |
Why?
| | Food | 1 | 2015 | 160 | 0.110 |
Why?
| | Rats | 4 | 2019 | 5639 | 0.110 |
Why?
| | Immunity, Innate | 1 | 2020 | 827 | 0.110 |
Why?
| | Immunotherapy | 1 | 2018 | 641 | 0.110 |
Why?
| | Microsatellite Repeats | 1 | 2014 | 168 | 0.100 |
Why?
| | Cytokines | 1 | 2021 | 2090 | 0.100 |
Why?
| | Multiprotein Complexes | 1 | 2015 | 163 | 0.100 |
Why?
| | Cyclic AMP | 1 | 2014 | 234 | 0.100 |
Why?
| | Liver Diseases | 1 | 2016 | 311 | 0.100 |
Why?
| | Molecular Chaperones | 1 | 2015 | 195 | 0.100 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 916 | 0.100 |
Why?
| | Signal Transduction | 4 | 2019 | 5078 | 0.100 |
Why?
| | Gene Knock-In Techniques | 1 | 2012 | 56 | 0.100 |
Why?
| | Endoplasmic Reticulum | 1 | 2015 | 264 | 0.100 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2019 | 612 | 0.100 |
Why?
| | Base Sequence | 2 | 2018 | 2182 | 0.100 |
Why?
| | Animals, Genetically Modified | 1 | 2012 | 240 | 0.090 |
Why?
| | Amino Acid Substitution | 1 | 2012 | 309 | 0.090 |
Why?
| | Gene Order | 1 | 2011 | 26 | 0.090 |
Why?
| | Models, Genetic | 1 | 2014 | 607 | 0.090 |
Why?
| | Retinitis Pigmentosa | 1 | 2011 | 20 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 1063 | 0.090 |
Why?
| | Severity of Illness Index | 3 | 2015 | 2836 | 0.090 |
Why?
| | Time Factors | 1 | 2022 | 6818 | 0.090 |
Why?
| | Intracellular Space | 1 | 2011 | 68 | 0.090 |
Why?
| | Young Adult | 5 | 2024 | 13163 | 0.090 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2015 | 752 | 0.090 |
Why?
| | Cell Line, Tumor | 2 | 2019 | 3414 | 0.090 |
Why?
| | Cell Membrane | 1 | 2014 | 737 | 0.090 |
Why?
| | Cytoskeletal Proteins | 1 | 2011 | 156 | 0.080 |
Why?
| | Sequence Alignment | 1 | 2011 | 345 | 0.080 |
Why?
| | Molecular Sequence Data | 2 | 2011 | 2904 | 0.080 |
Why?
| | Protein Transport | 1 | 2011 | 444 | 0.080 |
Why?
| | Penetrance | 1 | 2009 | 28 | 0.080 |
Why?
| | Sequence Analysis, DNA | 1 | 2012 | 812 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2021 | 10800 | 0.070 |
Why?
| | Gene Dosage | 1 | 2009 | 144 | 0.070 |
Why?
| | Child | 6 | 2022 | 21999 | 0.070 |
Why?
| | Autophagy | 2 | 2020 | 281 | 0.070 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2020 | 251 | 0.070 |
Why?
| | Infant | 3 | 2018 | 9451 | 0.060 |
Why?
| | Fetus | 1 | 2011 | 806 | 0.060 |
Why?
| | Fibroblasts | 1 | 2011 | 993 | 0.060 |
Why?
| | Child, Preschool | 3 | 2018 | 11080 | 0.060 |
Why?
| | Autophagy-Related Protein 7 | 1 | 2025 | 13 | 0.060 |
Why?
| | Regulatory-Associated Protein of mTOR | 1 | 2025 | 24 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 2 | 2015 | 3568 | 0.060 |
Why?
| | Adolescent | 4 | 2021 | 21499 | 0.060 |
Why?
| | Phosphorylation | 2 | 2019 | 1759 | 0.060 |
Why?
| | Aged | 4 | 2018 | 23851 | 0.050 |
Why?
| | Middle Aged | 5 | 2018 | 33310 | 0.050 |
Why?
| | CX3C Chemokine Receptor 1 | 1 | 2023 | 19 | 0.050 |
Why?
| | Receptors, Chemokine | 1 | 2023 | 47 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2011 | 2195 | 0.050 |
Why?
| | Cell Proliferation | 2 | 2019 | 2479 | 0.050 |
Why?
| | Genetic Background | 1 | 2021 | 11 | 0.040 |
Why?
| | Endocannabinoids | 1 | 2022 | 63 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2024 | 5436 | 0.040 |
Why?
| | Pravastatin | 1 | 2021 | 41 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 84 | 0.040 |
Why?
| | Inflammation | 2 | 2022 | 2836 | 0.040 |
Why?
| | Autophagy-Related Protein 12 | 1 | 2020 | 4 | 0.040 |
Why?
| | Autophagy-Related Protein 5 | 1 | 2020 | 8 | 0.040 |
Why?
| | Autophagy-Related Proteins | 1 | 2020 | 46 | 0.040 |
Why?
| | Major Histocompatibility Complex | 1 | 2021 | 227 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2019 | 4197 | 0.040 |
Why?
| | Apoptosis | 2 | 2019 | 2554 | 0.040 |
Why?
| | Leukocytes | 1 | 2021 | 312 | 0.040 |
Why?
| | NADH, NADPH Oxidoreductases | 1 | 2019 | 18 | 0.040 |
Why?
| | rab GTP-Binding Proteins | 1 | 2020 | 75 | 0.040 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2019 | 29 | 0.040 |
Why?
| | Rats, Inbred Lew | 1 | 2019 | 114 | 0.040 |
Why?
| | Suppressor of Cytokine Signaling 1 Protein | 1 | 2019 | 12 | 0.040 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2019 | 21 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2019 | 27 | 0.040 |
Why?
| | Receptors, Leukotriene | 1 | 2019 | 14 | 0.040 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2019 | 43 | 0.040 |
Why?
| | Aborted Fetus | 1 | 2018 | 1 | 0.040 |
Why?
| | Kidney Tubules, Proximal | 1 | 2019 | 127 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1700 | 0.040 |
Why?
| | Tamoxifen | 1 | 2019 | 202 | 0.040 |
Why?
| | Loop of Henle | 1 | 2018 | 1 | 0.040 |
Why?
| | Gene Silencing | 1 | 2019 | 195 | 0.040 |
Why?
| | Uromodulin | 1 | 2018 | 21 | 0.040 |
Why?
| | Nephrons | 1 | 1998 | 18 | 0.040 |
Why?
| | Myofibroblasts | 1 | 2019 | 126 | 0.040 |
Why?
| | Mixed Function Oxygenases | 1 | 1998 | 45 | 0.040 |
Why?
| | Ultrasonography | 2 | 2013 | 752 | 0.040 |
Why?
| | Cell Lineage | 1 | 2019 | 348 | 0.030 |
Why?
| | Genotype | 2 | 2016 | 1923 | 0.030 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 1998 | 158 | 0.030 |
Why?
| | Isoenzymes | 1 | 1998 | 304 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2019 | 436 | 0.030 |
Why?
| | RNA Splicing | 1 | 2018 | 268 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 2 | 2019 | 2486 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 455 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 413 | 0.030 |
Why?
| | Immunoprecipitation | 1 | 2016 | 155 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2016 | 387 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2016 | 388 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2016 | 324 | 0.030 |
Why?
| | CRISPR-Cas Systems | 1 | 2016 | 124 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1734 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2052 | 0.030 |
Why?
| | Forecasting | 1 | 2016 | 387 | 0.030 |
Why?
| | Heredity | 1 | 2013 | 13 | 0.030 |
Why?
| | Family | 1 | 2018 | 666 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2012 | 1061 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2021 | 3546 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2013 | 115 | 0.030 |
Why?
| | Genetic Linkage | 1 | 2013 | 298 | 0.020 |
Why?
| | Europe | 1 | 2013 | 414 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1774 | 0.020 |
Why?
| | Diagnostic Errors | 1 | 2013 | 170 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1274 | 0.020 |
Why?
| | Canada | 1 | 2013 | 421 | 0.020 |
Why?
| | Haplotypes | 1 | 2013 | 493 | 0.020 |
Why?
| | Genetic Testing | 1 | 2013 | 454 | 0.020 |
Why?
| | Family Health | 1 | 2009 | 197 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2032 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 7607 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2010 | 1484 | 0.020 |
Why?
| | Cytochrome P-450 CYP4A | 1 | 1998 | 4 | 0.010 |
Why?
| | Kidney Cortex | 1 | 1998 | 26 | 0.010 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1998 | 34 | 0.010 |
Why?
| | Kidney Medulla | 1 | 1998 | 35 | 0.010 |
Why?
| | Arterioles | 1 | 1998 | 52 | 0.010 |
Why?
| | Kidney Glomerulus | 1 | 1998 | 114 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1998 | 330 | 0.010 |
Why?
| | Sex Characteristics | 1 | 1998 | 765 | 0.010 |
Why?
| | RNA, Messenger | 1 | 1998 | 2839 | 0.010 |
Why?
| | Liver | 1 | 1998 | 1941 | 0.000 |
Why?
|
|
Hopp's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|